Metabolic Markers in Blood Can Separate Prostate Cancer from Benign Prostatic Hyperplasia

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Dec 4

PMID 26633561

Citations 44

Authors

Guro F Giskeodegard

Ailin Falkmo Hansen

Helena Bertilsson

Susana Villa Gonzalez

Kare Andre Kristiansen

Per Bruheim

Svein A Mjos

Anders Angelsen

Tone Frost Bathen

May-Britt Tessem

Affiliations

Soon will be listed here.

Abstract

Background: An individualised risk-stratified screening for prostate cancer (PCa) would select the patients who will benefit from further investigations as well as therapy. Current detection methods suffer from low sensitivity and specificity, especially for separating PCa from benign prostatic conditions. We have investigated the use of metabolomics analyses of blood samples for separating PCa patients and controls with benign prostatic hyperplasia (BPH).

Methods: Blood plasma and serum samples from 29 PCa patient and 21 controls with BPH were analysed by metabolomics analysis using magnetic resonance spectroscopy, mass spectrometry and gas chromatography. Differences in blood metabolic patterns were examined by multivariate and univariate statistics.

Results: By combining results from different methodological platforms, PCa patients and controls were separated with a sensitivity and specificity of 81.5% and 75.2%, respectively.

Conclusions: The combined analysis of serum and plasma samples by different metabolomics measurement techniques gave successful discrimination of PCa and controls, and provided metabolic markers and insight into the processes characteristic of PCa. Our results suggest changes in fatty acid (acylcarnitines), choline (glycerophospholipids) and amino acid metabolism (arginine) as markers for PCa compared with BPH.

Citing Articles

Metabolomic profile and its association with the diagnosis of prostate cancer: a systematic review.

Salinas Pita A, Mosquera Escudero M, Jimenez-Charris E, Garcia-Perdomo H J Cancer Res Clin Oncol. 2024; 151(1):29.

PMID: 39739063 PMC: 11688254. DOI: 10.1007/s00432-024-06058-w.

Subcellular NAD pools are interconnected and buffered by mitochondrial NAD.

Hoyland L, VanLinden M, Niere M, Stromland O, Sharma S, Dietze J Nat Metab. 2024; 6(12):2319-2337.

PMID: 39702414 DOI: 10.1038/s42255-024-01174-w.

The causal effect of serum amino acids on the risk of prostate cancer: a two-sample mendelian randomization study.

Miao L, Wang Q, Kan S, Liu W, Zhang Y, Chen W Sci Rep. 2024; 14(1):29720.

PMID: 39614073 PMC: 11607404. DOI: 10.1038/s41598-024-80986-y.

Tumor-Promoted Changes in Pediatric Brain Histology Can Be Distinguished from Normal Parenchyma by Desorption Electrospray Ionization Mass Spectrometry Imaging.

Seidinger A, Silva F, Euzebio M, Krieger A, Meidanis J, Gutierrez J Biomedicines. 2024; 12(11).

PMID: 39595159 PMC: 11592165. DOI: 10.3390/biomedicines12112593.

Serum urea concentration and risk of 16 site-specific cancers, overall cancer, and cancer mortality in individuals with metabolic syndrome: a cohort study.

Wu E, Wei G, Li Y, Du M, Ni J BMC Med. 2024; 22(1):536.

PMID: 39548477 PMC: 11566152. DOI: 10.1186/s12916-024-03758-5.

References

Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y . A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 2012; 7(7):e40459. PMC: 3394708. DOI: 10.1371/journal.pone.0040459. View

Cloarec O, Dumas M, Craig A, Barton R, Trygg J, Hudson J . Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem. 2005; 77(5):1282-9. DOI: 10.1021/ac048630x. View

Szlosarek P . Arginine deprivation and autophagic cell death in cancer. Proc Natl Acad Sci U S A. 2014; 111(39):14015-6. PMC: 4191809. DOI: 10.1073/pnas.1416560111. View

Osl M, Dreiseitl S, Pfeifer B, Weinberger K, Klocker H, Bartsch G . A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics. 2008; 24(24):2908-14. DOI: 10.1093/bioinformatics/btn506. View

Kim R, Coates J, Bowles T, McNerney G, Sutcliffe J, Jung J . Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 2009; 69(2):700-8. PMC: 2629384. DOI: 10.1158/0008-5472.CAN-08-3157. View

Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M . Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999; 36(1):31-5. DOI: 10.1159/000019923. View

Wuermli L, Joerger M, Henz S, Schmid H, Riesen W, Thomas G . Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis. 2005; 8(4):316-20. DOI: 10.1038/sj.pcan.4500834. View

Cairns R, Harris I, Mak T . Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2):85-95. DOI: 10.1038/nrc2981. View

Wulaningsih W, Holmberg L, Garmo H, Zethelius B, Wigertz A, Carroll P . Serum glucose and fructosamine in relation to risk of cancer. PLoS One. 2013; 8(1):e54944. PMC: 3556075. DOI: 10.1371/journal.pone.0054944. View

10.

Mihaleva V, van Schalkwijk D, de Graaf A, van Duynhoven J, van Dorsten F, Vervoort J . A systematic approach to obtain validated partial least square models for predicting lipoprotein subclasses from serum NMR spectra. Anal Chem. 2013; 86(1):543-50. DOI: 10.1021/ac402571z. View

11.

Sciotto C, Mjos S . Trans isomers of EPA and DHA in omega-3 products on the European market. Lipids. 2012; 47(7):659-67. DOI: 10.1007/s11745-012-3672-3. View

12.

Zha S, Ferdinandusse S, Hicks J, Denis S, Dunn T, Wanders R . Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate. 2004; 63(4):316-23. DOI: 10.1002/pros.20177. View

13.

Chuang C, Lin S, Lin Y, Huang F . Effects of anticoagulants in amino acid analysis: comparisons of heparin, EDTA, and sodium citrate in vacutainer tubes for plasma preparation. Clin Chem. 1998; 44(5):1052-6. View

14.

Kotani K, Sekine Y, Ishikawa S, Ikpot I, Suzuki K, Remaley A . High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013; 23(5):313-9. PMC: 3775524. DOI: 10.2188/jea.je20130006. View

15.

Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N . Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011; 117(10):2086-95. DOI: 10.1002/cncr.25758. View

16.

Wasta Z, Mjos S . A database of chromatographic properties and mass spectra of fatty acid methyl esters from omega-3 products. J Chromatogr A. 2013; 1299:94-102. DOI: 10.1016/j.chroma.2013.05.056. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Roehrborn C, Boyle P, Gould A, Waldstreicher J . Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999; 53(3):581-9. DOI: 10.1016/s0090-4295(98)00655-4. View

19.

Xia J, Mandal R, Sinelnikov I, Broadhurst D, Wishart D . MetaboAnalyst 2.0--a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012; 40(Web Server issue):W127-33. PMC: 3394314. DOI: 10.1093/nar/gks374. View

20.

Zhao Z, Xiao Y, Elson P, Tan H, Plummer S, Berk M . Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol. 2007; 25(19):2696-701. DOI: 10.1200/JCO.2006.08.5571. View